Hypoparathyroidism screening: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Hypoparathyroidism}} | {{Hypoparathyroidism}} | ||
{{CMG}}; {{AE | {{CMG}}; {{AE}} | ||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend routine screening for | There is insufficient evidence to recommend routine screening for hypoparathyroidism. However, a significant number of patients of isolated idiopathic hypoparathyroidism with hypercaliuria may have a de novo calcium-sensing receptor (CASR) gene mutation. All patient require treatment with 1-hydroxylated vitamin D3 for correction of hypocalcemia. As 1-hydroxylated vitamin D3 may precipitate prolonged episode of hypercalciuria, treatment decision should be evaluated on an individual basis in asymptomatic or mildly symptomatic patients. Molecular screening of CASR gene in patients with this presentation is recommended during initial work-up as it has potentially important clinical relevance to the patient’s prognosis. | ||
==Screening== | ==Screening== | ||
There is insufficient evidence to recommend routine screening for hypoparathyroidism. However, a significant number of patients of isolated idiopathic hypoparathyroidism with hypercaliuria may have a de novo calcium-sensing receptor (CASR) gene mutation. All patient require treatment with 1-hydroxylated vitamin D3 for correction of hypocalcemia. As 1-hydroxylated vitamin D3 may precipitate prolonged episode of hypercalciuria, treatment decision should be evaluated on an individual basis in asymptomatic or mildly symptomatic patients. Molecular screening of CASR gene in patients with this presentation is recommended during initial work-up as it has potentially important clinical relevance to the patient’s prognosis. | |||
==References== | ==References== | ||
Revision as of 19:58, 21 September 2017
|
Hypoparathyroidism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hypoparathyroidism screening On the Web |
|
American Roentgen Ray Society Images of Hypoparathyroidism screening |
|
Risk calculators and risk factors for Hypoparathyroidism screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is insufficient evidence to recommend routine screening for hypoparathyroidism. However, a significant number of patients of isolated idiopathic hypoparathyroidism with hypercaliuria may have a de novo calcium-sensing receptor (CASR) gene mutation. All patient require treatment with 1-hydroxylated vitamin D3 for correction of hypocalcemia. As 1-hydroxylated vitamin D3 may precipitate prolonged episode of hypercalciuria, treatment decision should be evaluated on an individual basis in asymptomatic or mildly symptomatic patients. Molecular screening of CASR gene in patients with this presentation is recommended during initial work-up as it has potentially important clinical relevance to the patient’s prognosis.
Screening
There is insufficient evidence to recommend routine screening for hypoparathyroidism. However, a significant number of patients of isolated idiopathic hypoparathyroidism with hypercaliuria may have a de novo calcium-sensing receptor (CASR) gene mutation. All patient require treatment with 1-hydroxylated vitamin D3 for correction of hypocalcemia. As 1-hydroxylated vitamin D3 may precipitate prolonged episode of hypercalciuria, treatment decision should be evaluated on an individual basis in asymptomatic or mildly symptomatic patients. Molecular screening of CASR gene in patients with this presentation is recommended during initial work-up as it has potentially important clinical relevance to the patient’s prognosis.